| Surface epithelial-stromal tumor |
| Classification and external resources |
High magnification micrograph of a Brenner tumor, a type of surface epithelial-stromal tumor. H&E stain. |
| ICD-10 |
C56, D27 |
| ICD-9 |
183, 220 |
Main article: Ovarian cancer
Surface epithelial-stromal tumors are a class of ovarian neoplasms that may be benign or malignant. Neoplasms in this group are thought to be derived from the ovarian surface epithelium (modified peritoneum) or from ectopic endometrial or Fallopian tube (tubal) tissue. Tumors of this type are also called ovarian adenocarcinoma.[1] This group of tumors accounts for 90% to 95% of all cases of ovarian cancer.[2] Serum CA-125 is often elevated but is only 50% accurate so it is not a useful tumor marker to assess the progress of treatment.
|
Contents
- 1 Classification
- 1.1 Serous tumors
- 1.1.1 Pathology
- 1.1.2 Prognosis
- 1.2 Mucinous tumors
- 1.2.1 Pathology
- 1.2.2 Prognosis
- 1.3 Endometrioid tumors
- 1.3.1 Pathology
- 1.3.2 Prognosis
- 1.4 Clear cell tumors
- 1.5 Brenner tumor
- 2 Treatment
- 3 Metastases
- 4 Effect on fertility
- 5 Additional images
- 6 Sources
- 7 References
- 8 External links
|
Classification
Ovarian cancers in women aged 20+, with area representing relative incidence and color representing 5-year relative survival rate.
[1] Surface epithelial-stromal tumors are labeled in center of the main diagram, and represent all types except the ones separated at top.
Epithelial-stromal tumors are classified on the basis of the epithelial cell type, the relative amounts of epithelium and stroma, the presence of papillary processes, and the location of the epithelial elements. Microscopic pathological features determine whether a surface epithelial-stromal tumor is benign, borderline, or malignant (evidence of malignancy and stromal invasion). Borderline tumors are of uncertain malignant potential.
This group consists of serous, mucinous, endometrioid, clear cell, and brenner (transitional cell) tumors, though there are a few mixed, undifferentiated and unclassified types.
Serous tumors
- These tumors vary in size from small and nearly imperceptible to large, filling the abdominal cavity.
- Benign, borderline, and malignant types of serous tumors account for about 30% of all ovarian tumors.
- 75% are benign or of borderline malignancy, and 25% are malignant
- The malignant form of this tumor, serous cystadenocarcinoma, accounts for approximately 40% of all carcinomas of the ovary and are the most common malignant ovarian tumors.
- Benign and borderline tumors are most common between the ages of 20 and 50 years.
- Malignant serous tumors occur later in life on average, although somewhat earlier in familial cases.
- 20% of benign, 30% of borderline, and 66% of malignant tumors are bilateral (affect both ovaries).
Components can include:
- cystic areas
- cystic and fibrous areas
- predominantly fibrous areas
The chance of malignancy of the tumor increases with the amount of solid areas present, including both papillary structures and any necrotic tissue present.
Pathology
- lined by tall, columnar, ciliated epithelial cells
- filled with clear serous fluid
- the term serous which originated as a description of the cyst fluid has come to be describe the particular type of epithelial cell seen in these tumors
- may involve the surface of the ovary
- the division between benign, borderline, and malignant is ascertained by assessing:
- cellular atypia (whether or not individual cells look abnormal)
- invasion of surrounding ovarian stroma (whether or not cells are infiltrating surrounding tissue)
- borderline tumors may have cellular atypia but do NOT have evidence of invasion
- the presence of psammoma bodies are a characteristic microscopic finding of cystadenocarcinomas[3]
Prognosis
The prognosis of a serous tumor, like most neoplasms, depends on
- degree of differentiation
- this is how closely the tumor cells resemble benign cells
- a well-differentiated tumor closely resembles benign tumors
- a poorly differentiated tumor may not resemble the cell type of origin at all
- a moderately differentiated tumor usually resembles the cell type of origin, but appears frankly malignant
- extension of tumor to other structures
- in particular with serous malignancies, the presence of malignant spread to the peritoneum is important with regard to prognosis.
The five year survival rate of borderline and malignant tumors confined to the ovaries are 100% and 70% respectively. If the peritoneum is involved, these rates become 90% and 25%.
While the 5-year survival rates of borderline tumors are excellent, this should not be seen as evidence of cure, as recurrences can occur many years later.
Mucinous tumors
Mucinous tumors:
- Closely resemble their serous counterparts
- Somewhat less common, accounting for about 25% of all ovarian neoplasms
- Occur principally in middle adult life and are rare before puberty and after menopause
- 80% are benign or borderline and about 15% are malignant
- Mucinous cystadenocarcinomas (the malignant form of this tumor) are relatively uncommon and account for only 10% of all ovarian cancers
- Mucinous tumors are characterized by more cysts of variable size and a rarity of surface involvement as compared to serous tumors
- Also in comparison to serous tumors, mucinous tumors are less frequently bilateral, approximately 5% of primary mucinous tumors are bilateral.
- May form very large cystic masses, with recorded weights exceeding 25 kg
- Appear as multiloculated tumors filled with sticky, gelatinous fluid
Pathology
Benign mucinous tumors are characterized by a lining of tall columnar epithelial cells with apical mucin and the absence of cilia, similar in appearance with benign cervical or intestinal epithelia. Cystadenocarcinomas (malignant tumors) contain a more solid growth pattern with the hallmarks of malignancy: cellular atypia and stratification, loss of the normal architecture of the tissue, and necrosis. The appearance can look similar to colonic cancer. Clear stromal invasion is used to differentiate borderline tumors from malignant tumors.
Prognosis
10-year survival rates for borderline tumors contained within the ovary, malignant tumors without invasion, and invasive malignant tumors are greater than 95%, 90%, and 66%, respectively. One rare but noteworthy condition associated with mucinous ovarian neoplasms is pseudomyxoma peritonei. As primary ovarian mucinous tumors are usually unilateral (in one ovary), the presentation of bilateral mucinous tumors requires exclusion of a non-ovarian origin.
Endometrioid tumors
Endometrioid tumors account for approximately 20% of all ovarian cancers and are mostly malignant (endometroid carcinomas). They are made of tubular glands bearing a close resemblance to benign or malignant endometrium. 15-30% of endometrioid carcinomas occur in individuals with carcinoma of the endometrium, and these patients have a better prognosis. They appear similar to other surface epithelial-stromal tumors, with solid and cystic areas. 40% of these tumors are bilateral, when bilateral, metastases is often present.
Pathology
- Glands bearing a strong resemblance to endometrial-type glands
- Benign tumors have mature-appearing glands in a fibrous stroma
- Borderline tumors have a complex branching pattern without stromal invasion
- Carcinomas (malignant tumors) have invasive glands with crowded, atypical cells, frequent mitoses. With poorer differentiation, the tumor becomes more solid.
Prognosis
Prognosis again is dependent on the spread of the tumor, as well as how differentiated the tumor appears. The overall prognosis is somewhat worse than for serous or mucinous tumors, and the 5-year survival rate for patients with tumors confined to the ovary is approximately 75%.
Clear cell tumors
Micrograph of an ovarian clear cell carcinoma. H&E stain.
Clear cell tumors are characterized by large epithelial cells with abundant clear cytoplasm and may be seen in association with endometriosis or endometrioid carcinoma of the ovary, bearing a resemblance to clear cell carcinoma of the endometrium. They may be predominantly solid or cystic. If solid, the clear cells tend to be arranged in sheets or tubules. In the cystic variety, the neoplastic cells make up the cyst lining.
Prognosis
These tumors tend to be aggressive, the five year survival rate for tumors confined to the ovaries is approximately 65%. If the tumor has spread beyond the ovary at diagnosis, the prognosis is poor
Brenner tumor
Brenner tumors are uncommon surface-epithelial stromal cell tumors in which the epithelial cell (which defines these tumors) is a transitional cell. These are similar in appearance to bladder epithelia. The tumors may be very small to very large, and may be solid or cystic. Histologically, the tumor consists of nests of the aforementioned transitional cells within surrounding tissue that resembles normal ovary. Brenner tumors may be benign or malignant, depending on whether the tumor cells invade the surrounding tissue.
Treatment
For more general information, see ovarian cancer.
For advanced cancer of this histology, the US National Cancer Institute recommends a method of chemotherapy that combines intravenous (IV) and intraperitoneal (IP) administration.[4] Preferred chemotherapeutic agents include a platinum drug with a taxane.
Metastases
For surface epithelial-stromal tumors, the most common sites of metastasis are the pleural cavity (33%), the liver (26%), and the lungs (3%).[5]
Effect on fertility
Fertility subsequent to treatment of surface epithelial-stromal tumors depends mainly on histology and initial staging to separate it into early borderline (or more benign) versus advanced stages of borderline (or more malignant).[6] Conservative management (without bilateral oophorectomy) of early stage borderline tumors have been estimated to result in chance of over 50% of spontaneous pregnancy with a low risk of lethal recurrence of the tumor (0.5%).[6] On the other hand, in cases of conservative treatment in advanced stage borderline tumors, spontaneous pregnancy rates have been estimated to be 35% and the risk of lethal recurrence 2%.[6]
Additional images
-
Brenner tumour. H&E stain.
Sources
- Braunwald, Eugene (2001). Harrison's principles of internal medicine (15th ed.). New York: McGraw-Hill. ISBN 0-07-913686-9.
- Haber, Meryl H. (2002). Differential diagnosis in surgical pathology. Philadelphia: W.B. Saunders. ISBN 0-7216-9053-X.
References
- ^ a b Kosary, Carol L. (2007). "Chapter 16: Cancers of the Ovary". In Baguio, RNL; Young, JL; Keel, GE; Eisner, MP; Lin, YD; Horner, M-J. SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988-2001, Patient and Tumor Characteristics. SEER Program. NIH Pub. No. 07-6215. Bethesda, MD: National Cancer Institute. pp. 133–144.
- ^ Bradshaw, Karen D.; Schorge, John O.; Schaffer, Joseph; Lisa M. Halvorson; Hoffman, Barbara G. (2008). Williams' Gynecology. McGraw-Hill Professional. ISBN 0-07-147257-6.
- ^ Cotran, Ramzi S.; Kumar, Vinay; Fausto, Nelson; Nelso Fausto; Robbins, Stanley L.; Abbas, Abul K. (2005). Robbins and Cotran pathologic basis of disease (7th ed.). St. Louis, Mo: Elsevier Saunders. ISBN 0-7216-0187-1.
- ^ NCI Issues Clinical Announcement for Preferred Method of Treatment for Advanced Ovarian Cancer, January 2006
- ^ [1] PMID 11844820: Epithelial Ovarian Cancer Metastasizing to the Brain: A Late Manifestation of the Disease With an Increasing Incidence
- ^ a b c Darai, E.; Fauvet, R.; Uzan, C.; Gouy, S.; Duvillard, P.; Morice, P. (2012). "Fertility and borderline ovarian tumor: A systematic review of conservative management, risk of recurrence and alternative options". Human Reproduction Update 19 (2): 151–166. doi:10.1093/humupd/dms047. PMID 23242913. edit
External links
- Johns Hopkins: "Surface Epithelial Tumors"
- Diagram: "Epithelial Stromal Ovarian Tumors"
|
Tumors: female urogenital neoplasia (C51–C58/D25–D28, 179–184/218–221)
|
|
| Adnexa |
|
Ovaries
|
Glandular and epithelial/
surface epithelial-
stromal tumor |
CMS: Ovarian serous cystadenoma · Mucinous cystadenoma · Cystadenocarcinoma (Papillary serous cystadenocarcinoma) · Krukenberg tumor
Endometrioid tumor · Clear-cell ovarian carcinoma · Brenner tumour
|
|
|
Sex cord-gonadal stromal
|
Leydig cell tumour · Sertoli cell tumour · Sertoli-Leydig cell tumour · Thecoma · Granulosa cell tumour · Luteoma · Sex cord tumour with annular tubules
|
|
|
Germ cell
|
Dysgerminoma · Nongerminomatous (Embryonal carcinoma, Endodermal sinus tumor, Gonadoblastoma, Teratoma/Struma ovarii, Choriocarcinoma)
|
|
|
Fibroma
|
Meigs syndrome
|
|
|
|
Fallopian tube
|
Adenomatoid tumor
|
|
|
| Uterus |
|
Myometrium
|
Uterine fibroids/leiomyoma · Leiomyosarcoma · Adenomyoma
|
|
|
Endometrium
|
Endometrioid tumor · Uterine papillary serous carcinoma · Clear cell carcinoma · Endometrial intraepithelial neoplasia
|
|
|
Cervix
|
Cervical intraepithelial neoplasia · SCC · Glassy cell carcinoma · Villoglandular adenocarcinoma
|
|
|
Placenta
|
Choriocarcinoma · Gestational trophoblastic disease
|
|
|
General
|
Uterine sarcoma · Mixed Müllerian tumor
|
|
|
| Vagina |
SCC · Botryoid rhabdomyosarcoma · Clear cell adenocarcinoma of the vagina · Vaginal intraepithelial neoplasia
|
|
| Vulva |
SCC · Melanoma · Papillary hidradenoma · Extramammary Paget's disease · Vulvar intraepithelial neoplasia
|
|
|
|
|
noco/cong/npls, sysi/epon
|
proc/asst, drug (G1/G2B/G3CD)
|
|
|
|
_omentum_invasion.jpg)
.jpg)